Comparative Pharmacology
Head-to-head clinical analysis: NORISODRINE versus NORISODRINE AEROTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORISODRINE versus NORISODRINE AEROTROL.
NORISODRINE vs NORISODRINE AEROTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at beta-1 and beta-2 adrenergic receptors, causing positive inotropic and chronotropic effects on the heart and bronchodilation.
Isoproterenol is a non-selective beta-adrenergic receptor agonist, primarily stimulating both β1 and β2 receptors, resulting in increased heart rate, myocardial contractility, and bronchodilation.
Intravenous: 0.5-5 mcg/min continuous infusion; initial rate 0.5 mcg/min, titrate to effect. Subcutaneous or intramuscular: 0.2 mg (0.2 mL of 1:1000 solution).
1 to 2 inhalations (0.08 to 0.16 mg) every 4 to 6 hours as needed for bronchospasm.
None Documented
None Documented
Terminal half-life is 2-3 minutes; too short for sustained action, requiring continuous IV infusion.
The terminal elimination half-life of isoproterenol is approximately 2-3 minutes following intravenous administration, due to rapid uptake into tissues and metabolism by catechol-O-methyltransferase (COMT). This short half-life necessitates continuous infusion for sustained effect.
Primarily renal excretion of unchanged drug (80-90%) and sulfate conjugates; minor biliary excretion (<5%).
Primarily renal excretion of unchanged drug and metabolites (sulfate conjugates). After intravenous administration, approximately 70-80% of the dose is excreted in urine within 24 hours, with less than 10% in feces.
Category C
Category C
Beta-Adrenergic Agonist
Beta-Adrenergic Agonist